Projected Income Statement: Merck & Co., Inc.

Forecast Balance Sheet: Merck & Co., Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 25,006 17,499 27,962 23,869 34,774 32,448 21,199 9,337
Change - -30.02% 59.79% -14.64% 45.69% -6.69% -34.67% -55.96%
Announcement Date 2/3/22 2/2/23 2/1/24 2/4/25 2/3/26 - - -
1USD in Million
Estimates

Cash Flow Forecast: Merck & Co., Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 4,448 4,388 3,863 3,372 4,112 3,695 3,760 3,863
Change - -1.35% -11.96% -12.71% 21.95% -10.14% 1.76% 2.73%
Free Cash Flow (FCF) 1 8,674 14,707 9,143 18,096 12,360 16,050 24,463 24,577
Change - 69.55% -37.83% 97.92% -31.7% 29.86% 52.42% 0.46%
Announcement Date 2/3/22 2/2/23 2/1/24 2/4/25 2/3/26 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Merck & Co., Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) 42.93% 44.58% 16.77% 43.47% 50.17% 32.2% 46.9% 47.87%
EBIT Margin (%) 36.33% 37.99% 10.33% 36.46% 41.19% 27.15% 42.16% 42.95%
EBT Margin (%) 28.5% 27.74% 3.14% 31.07% 32.41% 21.09% 37.3% 39.15%
Net margin (%) 26.79% 24.49% 0.61% 26.68% 28.08% 15.81% 30.51% 31.47%
FCF margin (%) 17.81% 24.81% 15.21% 28.2% 19.01% 24.1% 34.84% 32.76%
FCF / Net Income (%) 66.47% 101.29% 2,504.93% 105.72% 67.71% 152.37% 114.22% 104.08%

Profitability

        
ROA 13.23% 17.69% 3.56% 17.38% 17.73% 8.44% 16.64% 17.51%
ROE 41.1% 45.16% 9.18% 46.35% 45.52% 22.79% 40.43% 37.63%

Financial Health

        
Leverage (Debt/EBITDA) 1.2x 0.66x 2.77x 0.86x 1.07x 1.51x 0.64x 0.26x
Debt / Free cash flow 2.88x 1.19x 3.06x 1.32x 2.81x 2.02x 0.87x 0.38x

Capital Intensity

        
CAPEX / Current Assets (%) 9.13% 7.4% 6.43% 5.25% 6.33% 5.55% 5.36% 5.15%
CAPEX / EBITDA (%) 21.27% 16.6% 38.31% 12.09% 12.61% 17.23% 11.42% 10.76%
CAPEX / FCF (%) 51.28% 29.84% 42.25% 18.63% 33.27% 23.02% 15.37% 15.72%

Items per share

        
Cash flow per share 1 5.17 7.512 5.106 8.449 6.57 6.39 12.15 14.08
Change - 45.29% -32.02% 65.45% -22.23% -2.75% 90.21% 15.81%
Dividend per Share 1 2.64 2.8 2.96 3.12 3.28 3.377 3.485 3.681
Change - 6.06% 5.71% 5.41% 5.13% 2.97% 3.17% 5.64%
Book Value Per Share 1 15.11 18.12 14.84 18.29 21.03 22.76 28.04 34.26
Change - 19.96% -18.09% 23.22% 14.95% 8.27% 23.16% 22.19%
EPS 1 5.14 5.71 0.14 6.74 7.28 4.226 8.772 9.723
Change - 11.09% -97.55% 4,714.29% 8.01% -41.95% 107.57% 10.84%
Nbr of stocks (in thousands) 2,525,944 2,535,396 2,534,023 2,529,636 2,482,023 2,469,879 2,469,879 2,469,879
Announcement Date 2/3/22 2/2/23 2/1/24 2/4/25 2/3/26 - - -
1USD
Estimates
2026 *2027 *
P/E ratio 28.7x 13.8x
PBR 5.33x 4.33x
EV / Sales 4.99x 4.57x
Yield 2.78% 2.87%

EPS & Dividend

Y-o-Y evolution of P/E

Year-on-year evolution of the Yield

Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
120.15USD
Average target price
129.81USD
Spread / Average Target
+8.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Financials Merck & Co., Inc.